Trop-2 expression on treatment resistant cancer cells in castrate-resistant prostate cancer (CRPC) as a predictive biomarker for targeted therapy.
Kimberly Ku(University of Wisconsin–Madison), Howard I. Scher(Memorial Sloan Kettering Cancer Center), Manish Kohli(Mayo Clinic in Arizona), Jamie M. Sperger(University of Wisconsin–Madison), Scott T. Tagawa(Cornell University), Scott M. Dehm(University of Minnesota), Liguo Wang(Beijing Tongren Hospital), Liewei Wang(Mayo Clinic), Joshua M. Lang(University of Wisconsin–Madison)
Cited by 1
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k